Patrick W. McLaughlin, MD, presented “The Staggering Benefit of PSA Screening in Potentially Lethal Prostate Cancer” during the 24th Annual Southwest Prostate Cancer Symposium on April 11, 2019 in Scottsdale, Arizona.
How to cite: McLaughlin, Patrick W. “The Staggering Benefit of PSA Screening in Potentially Lethal Prostate Cancer” April 11, 2019. Accessed Dec 2024. https://grandroundsinurology.com/the-staggering-benefit-of-psa-screening-in-potentially-lethal-prostate-cancer/
The Staggering Benefit of PSA Screening in Potentially Lethal Prostate Cancer – Summary:
Patrick W. McLaughlin, MD, discusses the limitations of evidence that provide the basis for the United States Preventive Services Task Force’s (USPSTF’s) negative gradings for PSA screening. He argues that in the modern era, with the currently-available curative therapy for most lethal prostate cancers, intensive screening can allow early enough detection to provide patients opportunities for a cure.
About the Southwest Prostate Cancer Symposium
The Southwest Prostate Cancer Symposium (SPCS) is a multi-day conference that seeks to educate urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer. The topics focus on current technical aspects of diagnosis and treatment of localized and advanced disease, particularly regarding imaging, technology, and training in the related devices. Dr. McLaughlin presented this lecture during the 24th SPCS in 2019. In 2020, the 25th SPCS will also offer training sessions involving imaging, scanning, and prostate cancer treatment-related devices on site. Please visit this page in order to register for future SPCS meetings.
ABOUT THE AUTHOR
Bill McLaughlin, MD, is a Professor of Radiation Oncology at University of Michigan Medicine. He is the Medical Director of Community Practices at Providence Hospital in Southfield, Michigan, and the Assarian Cancer Center in Novi, Michigan. Dr. McLaughlin is a board-certified radiation oncologist with a special interest in prostate cancer. Dr. McLaughlin is a member of the American Society for Therapeutic Radiology and Oncology (ASTRO) and the American Brachytherapy Society (ABS). Dr. McLaughlin pioneered MRI-based treatment planning for prostate implants and external beam therapy. Incorporating MRI imaging led to the development of vessel-sparing radiation analogous to nerve-sparing prostatectomy. MRI-based evaluation post implant has improved the accuracy of implant checking and improved the quality of prostate implants. These techniques have vastly improved the quality of life for men with prostate cancer. The results of this research were published in the International Journal of Radiation Oncology, Biology, and Physics. Dr. McLaughlin participated in the design of the Assarian Cancer Center, which features an integrated healing arts center and a program to improve patient and family support at all stages of the cancer experience.